Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Fintel reports that on July 16, 2025, B of A Securities downgraded their outlook for Centene (NYSE:CNC) from Neutral to ...

Centene fell by 11.1 percent week-on-week, from $31.44 on July 11 to $27.95 last Friday—a new all-time low, as investors turned cautious ahead of its second quarter earnings results, further ...

Investing.com -- Shares of Centene (NYSE:CNC) plunged more than 32% in premarket trading Wednesday after the company pulled its 2025 guidance, citing unexpectedly poor risk adjustment results in ...

Shares of Centene are experiencing a historic collapse this week. Wednesday marked the worst single-day performance in the company's history.

Centene aims to be a top provider of government-sponsored health plans. Although it has grown at a solid clip organically, it also has made significant acquisitions—most notably WellCare in ...

Centene's Fair Value Cut, Uncertainty Rating Downgraded on Individual Plan and Medicaid Headwinds Julie Utterback Jul 2, 2025 Share ...

Centene's stock was suffering a record 39.2% selloff in recent trading, as a miscalculation of rising healthcare costs led the company to withdraw its full-year earnings outlook.

Meanwhile, Barclays downgraded Centene from Overweight to Equalweight, expressing concerns about the Part D and ACA segments and adjusting their earnings per share estimates downward for 2025 and ...

Jefferies downgraded Centene (CNC) to Underperform from Hold with a price target of $52, down from $68. After analysis of Affordable Care Act Exchange data, the firm sees potential for ...

Warning that its earnings will fall well short of expectations, managed-care giant Centene withdrew its financial guidance for 2025, causing its shares to plunge in after-hours trading Tuesday ...

On June 2, an analyst from Barclays downgraded Centene Corporation’s (NYSE:CNC) rating from Overweight to Equal-Weight and lowered its price target from $84 to $65. The downgrade follows Centene ...